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Initially identiﬁed to be activated upon virus infection, the double-stranded RNA–dependent protein kinase (PKR) is best
known for triggering cell defense responses by phosphorylating eIF-2, thus suppressing RNA translation. We as well as
others showed that the phosphorylation of PKR is down-regulated by insulin. In the present study, we further uncovered a
novel function of PKR in regulating the IRS proteins. We found that PKR up-regulates the inhibitory phosphorylation of IRS1
at Ser312, which suppresses the tyrosine phosphorylation of IRS1. This effect of PKR on the phosphorylation of IRS1 is
mediated by two other protein kinases, JNK and IKK. In contrast, PKR regulates IRS2, another major IRS family protein in the
liver, at the transcriptional rather than the posttranslational level, and this effect is mediated by the transcription factor, FoxO1,
which has been previously shown to be regulated by insulin and plays a signiﬁcant role in glucose homeostasis and energy
metabolism. In summary, we found for the ﬁrst time that initially known as a virus infection response gene, PKR regulates the
upstream central transmitters of insulin signaling, IRS1 and IRS2, through different mechanisms.
INTRODUCTION
Insulin signaling, a central signaling pathway that regulates
many cellular activities, such as glucose and lipid metabo-
lism, protein synthesis and degradation, and cell growth and
differentiation (Saltiel and Kahn, 2001), has been extensively
studied over the past decades. Insulin signaling is initiated
upon binding of insulin to the insulin receptor (IR), a recep-
tor tyrosine kinase (Patti and Kahn, 1998), and transmitted
intracellularly by the insulin receptor substrates (IRS; White,
1998). At least four of the IR substrates belong to the IRS
group, with IRS1 and IRS2 being predominant and ex-
pressed in most tissues, including the liver (White, 1998;
Thirone et al., 2006). On phosphorylation of the tyrosine
residues catalyzed by IR, the IRS proteins initiate, through
different binding mechanisms (White, 1998), various down-
stream signal transduction cascades, including mitogen-ac-
tivated protein kinase (MAPK), pathways (c-Jun N-terminal
kinase (JNK), extracellular signal–related kinase (ERK), p38
MAPK; Lowenstein et al., 1992; Skolnik et al., 1993), and
phosphoinositide 3-kinase (PI3K; Backer et al., 1992), which
in turn activates Akt/protein kinase B (Akt/PKB; Alessi et
al., 1997), and atypical protein kinase C (aPKC; Standaert et
al., 1997).
As one of the central signaling pathways regulating mul-
tiple fundamental cellular activities, insulin signaling is so-
phisticatedly tuned by a large number of regulators. Dys-
regulation of insulin signaling is closely related to the
development of insulin resistance (Sone et al., 2001) and
contributes to multiple diseases and disorders, such as type
2 diabetes as well as other metabolic, endocrine, and cardio-
vascular disorders (Reaven, 1988; Kahn, 1998; Sone et al.,
2001). At the molecular level, dysregulation of insulin sig-
naling could occur at several possible stages, e.g., degrada-
tion or mutation of IR (McElduff et al., 1984; Imamura et al.,
1994), inhibitory phosphorylation or degradation of IRS
(Zick, 2005; Herschkovitz et al., 2007), or suppression of
down-stream signaling molecules, such as PI-3 kinase or
Akt/PKB (reviewed in Taylor and Arioglu, 1998). However,
most of the regulation of insulin signaling occurs at the level
of the IRS proteins, the hub proteins that transmit signals
from IR to down-stream targets of insulin signaling (Zick,
2005; Herschkovitz et al., 2007). The phosphorylations of IRS
play critical roles in determining its activity. IRS proteins
mediate intracellular insulin signaling, through the tyrosine
residues, which facilitate recruitment of IRS substrates and
therefore promote insulin signaling (White, 1998), whereas
its phosphorylations at the serine residues generally sup-
press the activities of IRS by blocking the interaction be-
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3449tween IRS and IR (Paz et al., 1997), inhibiting the tyrosine
phosphorylation of IRS (Hotamisligil et al., 1996) or inducing
the degradation of IRS (Pederson et al., 2001). A number of
serine residues have been identiﬁed to negatively regulate
the activity of IRS1, in particular, Ser307 (equivalent to
Ser312 in human IRS1). Ser307 has been extensively inves-
tigated and characterized as a key indicator of inhibitory
serine phosphorylation of IRS1 and insulin resistance and
conﬁrmed in insulin-resistant rodent models (Hirosumi et
al., 2002). Interestingly, most of the down-stream targets of
insulin signaling, such as mammalian target of rapamycin
(mTOR; Ozes et al., 2001), PKC (Ravichandran et al., 2001),
S6 Kinase 1 (S6K1; Tremblay and Marette, 2001), and JNK
(Aguirre et al., 2000; Lee et al., 2003), have been shown to
function as IRS serine kinases, which are involved in the
negative feedback pathways of insulin signaling by promot-
ing the inhibitory serine phosphorylation of IRS1.
Initially identiﬁed as an antiviral protein, the double-
stranded RNA–dependent protein kinase (PKR) is best
known for triggering cell defense responses and initiating
innate immune responses by arresting general protein syn-
thesis and inducing apoptosis during virus infection (Proud,
1995). Until recently, PKR had not been reported to be
involved in the insulin signaling pathway. However, studies
have shown that insulin or insulin-like growth factor-I
(IGF-I) suppressed the phosphorylation of PKR in muscle
cells (Russell et al., 2007; Eley et al., 2008), by activating
protein phosphatase 1 (PP1) through the IRS–PI3K–Akt
pathway. We have found a similar inhibitory effect of insulin
on PKR in HepG2 cells (Wu et al., 2009). Given the feedbacks
involved in insulin signaling, we wanted to explore whether
PKR, as a downstream target of insulin signaling, is also able
to initiate a feedback pathway that functions on IRS1 phos-
phorylation. In fact, as a signal integrator of many intracel-
lular signaling events (Williams, 2001), PKR has been shown
to activate certain IRS kinases, e.g., IB kinase (IKK; Bonnet
et al., 2000; Gao et al., 2002) and JNK (Zhou et al., 2003; Yang
and Chan, 2009). Therefore, we investigated whether PKR is
involved in the induction of inhibitory Ser312 phosphoryla-
tion of IRS1 and if so, whether this effect is mediated by
other IRS kinases.
Because IRS1 and IRS2 are both expressed in liver cells, we
also investigated whether PKR affected IRS2. Our results
indicated that PKR regulates the gene transcription, rather
than the posttranslational modiﬁcation, of IRS2. The tran-
scription of the IRS2 gene has been shown to be up-regu-
lated by several transcription factors, such as forkhead box
O1 (FoxO1; Zhang et al., 2001; Ide et al., 2004) and cAMP
response element binding (CREB; Jhala et al., 2003). We
found that PKR enhanced the expression of IRS2 through
FoxO1, which regulates the transcription of IRS2 but not
IRS1. In summary, PKR, initially known as a virus infection
response gene, differentially regulates the major IRS pro-
teins, IRS1 and IRS2, which are central hubs in the insulin
signaling system.
MATERIALS AND METHODS
Cell Culture and Reagents
Human hepatoblastoma cells (HepG2/C3A) were cultured in Dulbecco’s
modiﬁed Eagle medium (DMEM; Invitrogen, Carlsbad, CA) with 10% fetal
bovine serum (FBS; Biomeda, Foster City, CA) and penicillin-streptomycin
(penicillin: 10,000 U/ml, streptomycin: 10,000 g/ml; Invitrogen). Freshly
trypsinized HepG2 cells were suspended at 5  105 cells/ml in standard
HepG2 culture medium and seeded at a density of 106 cells per well in
standard six-well tissue culture plates. After seeding, the cells were incubated
at 37°C in a 90% air/10% CO2 atmosphere, and 2 ml of fresh medium was
supplied every other day to the cultures after removal of the supernatant. The
HepG2 cells were cultured in standard medium for 5–6 d to achieve 90%
conﬂuence before any treatment. Human insulin and 2-aminopurine (2-
AP) were purchased from Sigma-Aldrich (St. Louis, MO), C2 ceramide,
tautomycetin, SC-514, okadaic acid (OA), PKR inhibitor, JNK inhibitor
(SP600125) and their analogues, used as negative controls, from EMD
Biosciences (San Diego, CA).
Insulin Treatment
Human insulin was stocked in HEPES buffer, which was therefore used in
controls for all the experiments with the insulin treatment. We treated the
cells with insulin at the concentrations lower than 1 nM to mimic the phys-
iological concentrations (Gual et al., 2003). Cells were deprived of serum for
16 h before insulin treatment.
Chemical Inhibitors
In the present study, we used the commercially available 2-AP and PKR
inhibitor as one of the tools to elucidate the role of PKR (data not shown).
However, even though these chemical have been widely used in the studies
of PKR for a variety of systems, the speciﬁcity of these inhibitor has not been
extensively tested in the literature. Keeping in mind the potential nonspeciﬁc
targets of these PKR inhibitors, we performed more PKR gene silencing and
overexpressing studies to test our hypothesis and draw the conclusions. The
JNK inhibitor, SP600125, IKK inhibitor, SC-514, PP1c inhibitor, TMC, and
PP2A inhibitor, OA are popularly used and have been proven to be speciﬁc
to their targets at the concentrations we used (Muranyi et al., 1997; Bennett et
al., 2001; Shim et al., 2002; Kishore et al., 2003; Mitsuhashi et al., 2003). All of
the inhibitors, except 2-AP, are dissolved in DMSO. 2-AP is dissolved in
glacial acetic acid solution in PBS (1:200; GA).
RNA Interference and Reverse Transfection
Silencer-validated small interfering RNA (siRNA) targeting human PKR,
JNK1, and JNK2 mRNAs and Silencer predesigned siRNAs targeting human
FoxO1, IRS1, and IRS2 mRNAs were purchased from Ambion (Austin, TX).
Prevalidated siRNA targeting human IKK mRNAs were purchased from
Qiagen (Valencia, CA). The synthesized oligonucleotides are 5-GGUGAAG-
GUAGAUCAAAGATT-3 and 5-UCUUUGAUCUACCUUCACCTT-3 for
siRNA of PKR, 5-GGGAUUUGUUAUCCAAAAUTT-3 and 5-AUUUUG-
GAUAACAAAUCCCTT-3 for siRNA of JNK1, 5-GGGAUUGUUU-
GUGCUGCAUTT-3 and 5-AUGCAGCACAAACAAUCCCTT-3 for siRNA
of JNK2, 5-GCUCAAAUGCUAGUACUAUTT-3 and 5-AUAGUACUAG-
CAUUUGAGCTA-3 for siRNA of FoxO1, 5-CCCAAGAGCAUGCA-
CAAACTT-3 and 5-GUUUGUGCAUGCUCUUGGGTT-3 for siRNA of
IRS1, 5-GCGAGUACAUCAACAUCGATT-3 and 5-UCGAUGUUGAU-
GUACUCGCCG-3 for siRNA of IRS2. The prevalidated siRNA of IKK was
designed to target the mRNA sequence AAACCGAGTTTGGGATCACAT. As
described previously (Yang and Chan, 2009), reverse transfection of siRNA
was performed with the transfection reagent, Lipofectamine RNAiMAX (In-
vitrogen). The scrambled nontargeting siRNA was used as a negative control.
Titration of the siRNA and the transfection reagent was performed (not
shown), and the lowest working amounts of the siRNA and the transfection
reagent were applied in the loss-of-function (LOF) experiments in the present
study.
Overexpression of PKR and Forward Transfection
The PKR plasmid, pCMV6-XL5-hPKR, and the empty vector, pCMV6-XL5,
were purchased from Origene (Rockville, MD). In general, as described
previously (Yang and Chan, 2009), regular HepG2 cells (see Figure 5C) or cells
with the other gene silenced by the siRNAs (see Figures 3B and 5E) were
subjected to forward transfections of the plasmids according to the Lipo-
fectamine 2000 (Invitrogen) method. After6ho ftransfection, the cells were
then cultured in regular media for 42 h, and harvested (Figure 5E) or treated
with other chemicals (Figures 3B and 5C) subsequently.
Western Blot Analysis and Immunoprecipitation
HepG2 cells were lysed as described previously (Yang and Chan, 2009). Total
protein levels were quantiﬁed by bicinchoninic acid (BCA) assay kit from
Pierce Biotechnology (Rockford, IL). Twenty to 40 g of total protein was
resolved by SDS-PAGE gels from Bio-Rad (Hercules, CA), transferred to
nitrocellulose membranes, and probed with primary and secondary antibod-
ies. Biotinylated protein ladders (Cell Signaling, Beverly, MA) were loaded to
one well of each SDS-PAGE gel, and anti-biotin antibody was used to detect
the protein ladders on Western blots. Antibody detection was performed
using the enhanced chemiluminescence kit from Pierce Biotechnology and
imaged on the Molecular Imager ChemiDoc XRS System from Bio-Rad.
Immunoprecipitation was performed as described previously (Yang and
Chan, 2009). The Western blots were quantiﬁed using the Quantity One
software (Bio-Rad). Phospho site-speciﬁc anti-IRS1 (Tyr941), PPP1A (Thr320),
and anti-PPP1A antibodies were purchased from Abcam (Cambridge, MA);
phospho site-speciﬁc anti-IKK/ (Ser176/180), FoxO1 (Ser256), anti-biotin,
anti-IKK, and anti-FoxO1 antibodies from Cell Signaling; and phospho
site-speciﬁc anti-IRS1 (Ser312), IRS2 (Ser731), PKR (Thr451), JNK (T183/
X. Yang et al.
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from Sigma-Aldrich. Secondary anti-rabbit and anti-mouse antibodies were
purchased from Pierce Biotechnology.
Real-Time Quantitative RT-PCR Analysis
Total RNA was extracted from cells with the RNeasy mini kit (Qiagen) and
depleted of contaminating DNA with RNase-free DNase (Qiagen). Equal
amounts of total RNA (1 g) were reverse-transcribed using an iScript cDNA
synthesis kit (Bio-Rad). The ﬁrst-strand cDNA was used as a template. The
primers used for quantitative RT-PCR analyses of human IRS1 (5-TCCAC-
CTCGGATTGTCTCTT-3 and 5-AGGGACTGGAGCCATACTCA-3), hu-
man IRS2 (5-CCACTCGGACAGCTTCTTCT-3 and 5-AGGATGGTCTCGT-
GGATGTT-3), and human GAPDH (5-AACTTTGGTATCGTGGAAGGA-3
and 5-CAGTAGAGGCAGGGATGATGT-3) were synthesized by Operon
Biotechnologies (Huntsville, AL). RT-PCR was performed As described pre-
viously, and normalized to GAPDH expression levels (Yang and Chan, 2009).
PP2A Phosphatase Activity Assay
The PP2A immunoprecipitation phosphatase assay kit purchased from Mil-
lipore (Temecula, CA) was used to measure dephosphorylation of a phos-
phopeptide as an index of phosphatase activity. Brieﬂy, the cells were lysed
using the phosphatase extraction buffer speciﬁed by the assay kit, and the
catalytic subunit of PP2A (PP2A/C) was immunoprecipitated with anti-
PP2A-C supplied in the assay kit. Agarose-bound immune complexes were
collected and resuspended in 80 l of Ser/Thr buffer with 750 M of phos-
phopeptide (KRpTIRR; obtained from the kit). The reaction was conducted for
10 min at 30°C in a shaking incubator. Supernatants (25 l) were transferred
in a 96-well plate, and released phosphate was measured by adding 100 lo f
malachite green phosphate detection solution. Color was developed for 10
min before reading the plate at 650 nm. The absorbance of the reactions was
corrected by subtracting the absorbance in samples treated without Ab.
Results were expressed as fold change of PP2A activity compared with
control cells.
Statistical Analysis
All experiments were performed at least three times, and representative
results are shown. All data, unless speciﬁed, are shown as the mean  SD for
indicated number of experiments. One-way ANOVA with Student’s t test was
used to evaluate statistical signiﬁcances between different treatment groups.
RESULTS
PKR Induces the Phosphorylation of IRS1 at Ser312
and Mediates the Effects of Ceramide on IRS1
Phosphorylation
We as well as others showed that the phosphorylation of
PKR is down-regulated by insulin through the IRS proteins
(Russell et al., 2007; Eley et al., 2008; Wu et al., 2009). We then
further studied whether feedback exists between PKR and
the IRS proteins. To evaluate the potential function of PKR
on the phosphorylation of IRS1, we silenced PKR with a
previously validated siRNA, which signiﬁcantly reduced the
PKR mRNA, protein, and phosphorylation levels (Yang and
Chan, 2009; Figure 1A). PKR, known as an eIF-2 kinase,
directly binds to eIF-2 and induces the phosphorylation of
eIF-2 at Ser51 (Taylor et al., 2005). Therefore the phosphor-
ylation of eIF-2 at Ser51 is considered to directly indicate
the kinase activity of PKR (Woldehawariat et al., 1999; Pataer
Figure 1. Involvement of PKR in regulating
the phosphorylation of IRS1. Reverse transfec-
tion of suspended HepG2 cells was performed
with scrambled siRNA (negative control) or
siRNA of PKR for 24 h, and the transfected
cells were cultured in regular media for an-
other 24 h (A). Cells were then treated with
different concentrations of insulin for 15 min
and harvested after the treatment (A). HepG2
cells were exposed to 5 M PKR inhibitor (PI)
or its analogue as a negative control (NC) or 10
mM 2-AP dissolved in PBS:glacial acetic acid
(200:1; GA, control) for 12 h followed by the
treatment of 0.2 nM insulin for 15 min (B).
Western blot analysis was performed to detect
the levels of -actin and PKR and the total and
phosphorylated levels of PKR and IRS1. The
phosphorylation levels of IRS1 at Ser312 and
Tyr941 were quantiﬁed by normalizing to total
IRS1 levels and are expressed as the average of
three samples  SD from three independent
experiments (A, middle and bottom). Stu-
dent’s t test was performed for analyzing the
differences between samples transfected with
siPKR and scrambled siRNA (negative control;
A). Signiﬁcantly higher (Tyr941) or lower
(Ser312) than negative control; i.e., scrambled
siRNA; *p  0.01.
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eIF-2 at Ser51 was shown to be highly correlated with the
phosphorylation of PKR at Thr451 or its activity (Woldeha-
wariat et al., 1999; Pataer et al., 2002; Morimoto et al., 2004;
Zhang et al., 2008). We conﬁrmed that gene silencing of PKR
signiﬁcantly reduced the phosphorylation of eIF-2 at Ser51
(Supplementary Figure 1), indicating that gene silencing
indeed reduced the overall kinase activity of PKR. Silencing
PKR in HepG2 cells signiﬁcantly blocked the Ser312 and
ampliﬁed the Tyr941 phosphorylation of IRS1 induced by
insulin (Figure 1A). To further conﬁrm a catalytic role of
PKR in regulating apoptosis, we inhibited the activity of
PKR with pharmaceutical inhibitors of PKR, PKR inhibitor
(PI; Jammi et al., 2003) and 2-AP (Ben-Asouli et al., 2002).
They suppressed the Ser312 and ampliﬁed the Tyr941 phos-
phorylation of IRS1 (Figure 1B), similar to the siRNA of
PKR. These results suggest that PKR induces the inhibitory
phosphorylation of IRS1 at Ser312 in HepG2 cells, thereby
suppressing the phosphorylation at Tyr941.
Indeed, a PKR activator (Ruvolo et al., 2001), ceramide, has
been shown to inhibit IRS1 activity by up-regulating the Ser
phosphorylation and blocking the Tyr phosphorylation of
IRS1 (Kanety et al., 1996; Miura et al., 2003). Given the effects
of PKR on the phosphorylation of IRS1, we further asked
whether PKR mediates the up-regulation of the serine and
down-regulation of the tyrosine phosphorylation of IRS1 by
ceramide through gene silencing and inhibition studies.
We ﬁrst conﬁrmed that ceramide induces the phosphory-
lation of PKR at Thr451, promotes phosphorylation of IRS1
at Ser312, and suppresses phosphorylation at Tyr941 in
HepG2 cells (Figure 2, A and B). Furthermore, in ceramide-
treated cells, silencing the gene expression of PKR reduced
the phosphorylation of IRS1 at Ser312 to control level (Fig-
ure 2B), which is consistent with the recovery IRS1 phos-
phorylation at Tyr941 in response to insulin (Figure 2B).
Inhibiting PKR with PI or 2-AP had a similar effect as PKR
silencing in blocking the effects of ceramide on the phos-
phorylation of IRS1 (Figure 2, C and D).
Taken together, both the gene silencing and inhibition
studies suggest that PKR may be involved in regulating
insulin signaling by inducing phosphorylation of IRS1 at
Ser312 and suppressing phosphorylation at Tyr941. This
function of PKR provides a potential mechanism by which
ceramide regulates IRS1 phosphorylation. However, it is
unclear how PKR regulates the phosphorylation of IRS1.
Coimmunoprecipitation showed that PKR did not directly
interact with IRS1 (Supplementary Figure 2), even upon
activation of PKR by ceramide (data not shown), suggesting
other intermediate signaling molecules must mediate the
effect of PKR on the phosphorylation of IRS1. IRS1 Ser
kinases, which directly phosphorylate the serine residues of
IRS1, include IKK (Gao et al., 2002), mTOR (Ozes et al., 2001),
PKC (Ravichandran et al., 2001), S6K1 (Tremblay and Ma-
rette, 2001), and JNK (Aguirre et al., 2000; Lee et al., 2003).
PKR has been reported to positively activate IKK (Bonnet et
al., 2000) and the MAPKs, in particular JNK (Zhou et al.,
2003; Yang and Chan, 2009). Therefore, we hypothesize that
PKR induces phosphorylation of IRS1 at Ser312 through IRS
serine kinases: JNK, IKK, or both.
PKR Positively Regulates JNK and IKK, Both of Which
Mediate the Effect of PKR on the Ser Phosphorylation of
IRS1
We previously showed that PKR coimmunoprecipitates
with JNK and activates JNK in HepG2 cells (Yang and Chan,
2009). Here, we show that IKK also is activated by PKR.
Silencing PKR (Yang and Chan, 2009) signiﬁcantly reduced
the phosphorylation of IKK/ at Ser176/180 (Figure 3A),
which indicates IKK activity. To further conﬁrm the involve-
ment of JNK and IKK in mediating the effect of PKR on the
phosphorylation of IRS1 at Ser312 and Tyr941, we overex-
pressed PKR in HepG2 cells and silenced or inhibited JNK or
Figure 2. PKR mediates the effects of ceramide on the
phosphorylation of IRS1. HepG2 cells were exposed to
different levels of ceramide for 12 h (A). Reverse trans-
fection of suspended HepG2 cells was performed with
scrambled siRNA (negative control) or siRNA of PKR
for 24 h, and the transfected cells were cultured in
regular media for another 12 h (B). Cells were then
treated with ceramide (10 M) for 12 h followed by
insulin (0.5 nM) treatment for 15 min (B). Pretreated
with 10 M ceramide for 12 h, HepG2 cells were ex-
posed to different levels of PKR inhibitor dissolved in
DMSO (control; C) or 10 mM 2-AP dissolved in PBS:
glacial acetic acid (200:1; GA, control; D) for another
12 h. After treatment, the cells were harvested, and
Western blot analysis was performed to detect the level
of -actin and the total and phosphorylated levels of
PKR and IRS1.
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the phosphorylation of eIF-2 (Supplementary Figure 1),
indicating that overexpression indeed up-regulates the over-
all kinase activity of PKR. Overexpressing PKR by transfect-
ing the plasmid pCMV6-hPKR into HepG2 cells enhanced
phosphorylation of IRS1 at Ser312 and suppressed phos-
phorylation at Tyr941 (Figure 3B), supporting our previous
results that PKR induces serine phosphorylation of IRS1 at
Ser312 (Figures 1 and 2). Furthermore, in PKR-overexpress-
ing cells, silencing the gene expression of JNK1/2 or IKK
signiﬁcantly reduced Ser312 phosphorylation and restored
Tyr941 phosphorylation of IRS1 in response to insulin (Fig-
ure 3B), suggesting that both kinases, JNK and IKK, mediate
the effect of PKR on the phosphorylation of IRS1 at Ser312
and in turn the suppression of the tyrosine phosphorylation
of IRS1. This was also supported by inhibiting JNK or IKK
using their respective speciﬁc chemical inhibitor, SP600125
or SC-514 (quantiﬁed Western blots results are shown in
Supplementary Figure 3; Wu et al., 2009).
In addition to IRS1, we also investigated the potential
effect of PKR on another major IRS family protein, IRS2,
which also mediates insulin signaling in the liver (Thirone et
al., 2006).
PKR Up-Regulates the Protein Expression Level of IRS2
Silencing the gene expression of PKR (Figure 1) down-reg-
ulated the protein level of IRS2 (Figure 4A), but not IRS1
(Figure 1), suggesting that PKR is required for cells to main-
tain proper protein expression level of IRS2. Similarly, both
PKR inhibitors (Figure 1), PKR inhibitor (PI) and 2-AP, also
down-regulated the protein level of IRS2 (Figure 4B), further
supporting the effect of PKR on the protein expression level
of IRS2. Therefore, PKR exploits a regulatory role on the
protein level of IRS2, but not on IRS1. As discussed above,
PKR affects IRS1 serine phosphorylation (Figures 1–3). No-
tably, upon inhibiting or silencing PKR, the phosphorylation
of IRS2 at Ser731 varied proportionally to its total protein
level (Figure 4, A and B), suggesting that PKR is not affecting
the phosphorylation of IRS2 at Ser731. As expected, the
general tyrosine phosphorylation of IRS2, normalized to the
total protein level of IRS2, is not affected by PKR silencing or
inhibition, as measured by Western blotting of the IRS2
immunoprecipitates with anti-phospho tyrosine antibody
(data not shown). Next, to determine whether PKR tran-
scriptionally regulates the protein level of IRS2, we mea-
sured the mRNA expression levels of IRS1 and IRS2 upon
PKR inhibition and gene silencing. Both the PKR inhibitors
and the siRNA of PKR down-regulated the mRNA expres-
sion of IRS2, but not of IRS1 (Figure 4, C and D), suggesting
that PKR regulates IRS2 at the transcriptional level.
PKR Up-Regulates the Protein Level of IRS2 through the
Transcription Factor FoxO1
PKR as a protein kinase, activates several transcription fac-
tors, such as IRF-1, p53, and nuclear factor kappa B (NF-B;
Kumar et al., 1997; Cuddihy et al., 1999), but these transcrip-
tion factors have not been shown to regulate the transcrip-
tion of IRS2. However, the transcription of IRS2 has been
shown to be dependent on the transcription factor FoxO1 in
the liver (Zhang et al., 2001; Ide et al., 2004) or CREB in
pancreatic -cells (Jhala et al., 2003). It is not known whether
PKR interacts with either of these two transcription factors.
We found that PKR had no effect on the activity or translo-
cation of CREB in HepG2 cells (not shown). However, si-
lencing the PKR gene signiﬁcantly increased the phosphor-
ylation of FoxO1 at Ser256 (Figure 5A). Phosphorylation at
Ser256 inhibits the DNA-binding activity of FoxO1 and its
nuclear import by suppressing the nuclear targeting signal
on its DNA-binding domain (Rena et al., 2001, 2002). We also
performed nuclear extraction and measured the nuclear
level of p-FoxO1 Ser256 in response to PKR silencing (Sup-
plementary Figure 4A). The nuclear level of the p-FoxO1
Ser256 was signiﬁcantly increased upon silencing of PKR,
further conﬁrming that PKR regulates FoxO1 activity by
regulating its phosphorylation and translocation. Our re-
sults suggest, for the ﬁrst time, that PKR reduces the phos-
phorylation of FoxO1 and thereby activates it. As a protein
kinase, PKR does not have the phosphatase activity that is
required to dephosphorylate FoxO1. However, PKR is
known to phosphorylate B56, the regulatory subunit of
PP2A, which then activates the catalytic subunit of PP2A
(Xu and Williams, 2000). PP2A, in turn, is known to dephos-
phorylate FoxO1 at Ser256 (Yan et al., 2008). Indeed, silenc-
Figure 3. Involvement of JNK and IKK in regulating the phosphor-
ylation of IRS1. Reverse transfection of suspended HepG2 cells was
performed with scramble siRNA (negative control) or siRNA of
PKR (siPKR) for 24 h, and the transfected cells were cultured in
regular medium for another 24 h (A). Cells were harvested, and
Western blot analysis was performed to detect the total and phos-
phorylated levels of JNK and IKK (A). Reverse transfection of
suspended HepG2 cells was performed with scrambled siRNA (con-
trol) or siRNAs of JNK1 and JNK2 together or siRNA of IKK for
24 h, and the transfected cells were cultured in regular media for
another 24 h. Next, the forward transfection of empty vector
pCMV6-XL5 (pCMV6) or plasmid containing PKR cDNA se-
quence (pCMV6-hPKR) was performed, followed by insulin
treatment (0.5 nM) for 15 min (B). After treatment, cells were then
harvested, and Western blot analysis was performed to detect the
protein level of IKK and JNK and total and phosphorylated levels
of PKR and IRS1 (B).
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ure 5B), thereby conﬁrming that PKR activates PP2A in
HepG2. To further investigate the potential involvement of
PP2A in mediating the dephosphorylation of Ser256 on
FoxO1 by PKR, we overexpressed PKR in HepG2 cells and
inhibited the activity of PP2A with OA. Overexpressing PKR
by transfecting the plasmid pCMV6-hPKR into HepG2 cells
reduced the phosphorylation of FoxO1 at Ser256 (Figure 5C),
supporting our results that PKR induces dephosphorylation
of FoxO1 at Ser256 (Figure 5A). More importantly, OA, a
speciﬁc PP2A inhibitor, restored the serine phosphorylation
level of FoxO1 in PKR overexpressed cells (Figure 5C). Sim-
ilarly overexpressing PKR also decreased the Ser256 phos-
phorylation of FoxO1 in the nucleus, and OA restored the
nuclear level of p-FoxO1 Ser256 in PKR overexpressed cells
(Supplementary Figure 4B). Taken together, PKR dephos-
phorylates and activates FoxO1, mediated by PP2A.
To conﬁrm the positive effect of FoxO1 on the expression
of IRS2 in HepG2 cells, we performed gene silencing of
FoxO1. Silencing the gene expression of FoxO1 signiﬁcantly
reduced the protein level of IRS2, but not IRS1 (Figure 5D),
suggesting that FoxO1 controls the expression of IRS2 in
HepG2 cells. To further conﬁrm that FoxO1 mediates the
effect of PKR on IRS2 protein level, we overexpressed PKR
in HepG2 cells as well as silenced FoxO1. Overexpressing
PKR in HepG2 cells increased the protein level of IRS2 (lanes
1 vs. 2 in Figure 5E), whereas silencing FoxO1 in control and
PKR overexpressed cells signiﬁcantly reduced the protein
level of IRS2 (Figure 5E), conﬁrming that PKR up-regulates
the protein level of IRS2 through the transcription factor
FoxO1.
In summary, our results suggest PKR differentially regu-
lates IRS proteins (Figure 6). First, PKR induces phosphor-
ylation of IRS1 at Ser312 and suppresses tyrosine phosphor-
ylation of IRS1, mediated by the IRS kinases, JNK and IKK.
Second, PKR activates a transcription factor, FoxO1, which
up-regulates the gene expression of IRS2. In addition, we as
well as others have identiﬁed PKR as a downstream sub-
strate of insulin signaling. Therefore taken together, our
results suggest that PKR is involved in insulin signaling
through a feedback mechanism and regulates the central
transmitters of intracellular insulin signaling in the liver,
IRS1, and IRS2, through different pathways (Figure 6).
DISCUSSION
In the present study, we identiﬁed the effects of PKR on two
major IRS proteins, IRS1 and IRS2, in HepG2 cells. First, PKR
up-regulates the phosphorylation of IRS1 at Ser312, which in
turn suppresses the tyrosine phosphorylation of IRS1. This
effect of PKR is mediated by JNK and IKK (Figure 3). It is
well known that PKR stimulates the transcription factor
NF-B by activating IKK (Bonnet et al., 2000), and this pro-
cess does not require the catalytic activity of PKR. Instead,
The N-terminus of PKR is responsible for the activation of
IKK (Bonnet et al., 2006). As discussed previously (Yang and
Chan, 2009), PKR has been reported also to play a role in the
phosphorylation of the three MAPKs: JNK, ERK, and p38
MAPK, in the rank order of JNK  p38 MAPK  ERK (Zhou
et al., 2003). Among the three MAPKs, JNK has been sug-
gested to play a central role in inducing the inhibitory serine
phosphorylation of IRS1 (Aguirre et al., 2000; Hirosumi et al.,
2002). We did not test the effects of PKR on the other two less
responsive MAPK proteins, ERK and p38 MAPK, which
were also suggested to induce phosphorylation of IRS1 at
Figure 4. Involvement of PKR in regulating
IRS2. Reverse transfection of suspended HepG2
cells was performed with scrambled siRNA
(negative control) or siRNA of PKR for 24 h, and
the transfected cells were cultured in regular
media for another 24 h. Cells were then har-
vested (D) or treated with different concentra-
tions of insulin for 15 min and harvested after
the treatment (A). Conﬂuent HepG2 cells were
treated with 5 M PKR inhibitor (PI) or its ana-
logue as a negative control (NC) or 10 mM 2-AP
dissolved in PBS:glacial acetic acid (200:1) (GA)
for 12 h (B and C). Western blot analysis was
performed to detect the total and phosphory-
lated levels of IRS2 at Ser731 (A and B). RT-PCR
was performed to detect the gene expression
levels of IRS1 and IRS2 in response to the PKR
inhibitors (C) or siRNA of PKR (D). Gene expres-
sion data were expressed as the average of nine
samples  SD from three independent experi-
ments. The protein levels of IRS2 were quanti-
ﬁed by normalizing to -actin, and the phos-
phorylation levels of IRS2 at Ser731 were
quantiﬁed by normalizing to total IRS2 levels.
Both the protein and phosphorylation levels of
IRS2 are expressed as the average of three sam-
ples  SD from three independent experiments.
Student’s t test was performed for analyzing the
differences between siPKR and scrambled
siRNA (negative control). Signiﬁcantly lower
than negative control; i.e., scrambled siRNA (A
and D) or chemical analogue of the PKR inhibi-
tor (B and C); *p  0.05. Signiﬁcantly lower than
control; GA, solvent of 2-AP; **p  0.05.
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although JNK may be an important intermediate, it is not
likely the only one involved in mediating the signaling
pathway from PKR to IRS1 phosphorylation.
The phosphorylation of IRS1 at Ser312 by PKR provides a
potential mechanism through which ceramide, an activator
of PKR, promotes the inhibitory serine phosphorylation of
IRS1. Indeed, other activators of PKR have also been shown
to function on IRS1 in a similar manner. For example, HCV
core protein, which directly binds and activates PKR (Yan et
al., 2007), has been shown to induce the phosphorylation of
IRS1 at Ser312 (Banerjee et al., 2008). The ability of PKR to
promote serine phosphorylation of IRS1 provides a possible
mechanism by which PKR mediates HCV infection and the
inhibition of the IRS1 activity (Aytug et al., 2003; Banerjee et
al., 2008).
A novel function of PKR that we uncovered is its regula-
tion of the protein level of IRS2 through the transcription
factor FoxO1. The effect of PKR on FoxO1 has not been
studied previously. We show that PKR dephosphorylates
and activates FoxO1 mediated by the protein phosphatase
PP2A. FoxO1 directs the expression of genes involved in a
wide variety of cellular responses, one of which is the reg-
ulation of glucose homeostasis and energy metabolism
(Gross et al., 2008). Insulin induces the phosphorylation of
FoxO1, thereby inhibiting its activity (Barthel et al., 2005). In
healthy states, the low insulin level during fasting sustains
the activity of FoxO1, which facilitates the transcription of
key enzymes involved in gluconeogenesis (Puigserver et al.,
2003). FoxO1 also can up-regulate IRS2 gene expression
through a feedback loop (Zhang et al., 2001; Ide et al., 2004),
which occurs in HepG2 cells (Figure 5). However in insulin
resistance models, the persistent activation of FoxO1, due to
disruption of the IRS–PI3K–Akt pathway, contributes to the
development of hyperglycemia and glucose intolerance
(Samuel et al., 2006; Dong et al., 2008). Therefore, FoxO1,
which becomes activated during insulin resistance, is be-
lieved to serve as a dominant regulator of hepatic gene
expression. The roles of FoxO1 in regulating fasting glucose
homeostasis and enhancing hyperglycemia and glucose in-
tolerance in insulin resistance models begs the question of
whether PKR activation is involved in the regulation of
glucose metabolism mediated by FoxO1.
Given the inhibitory effect of insulin on PKR and the
regulation of FoxO1 phosphorylation by PKR, we hypothe-
size that insulin-stimulated FoxO1 phosphorylation is me-
diated by PKR (Figure 6). However, it has been previously
shown that insulin stimulates the FoxO1 phosphorylation
through Akt, which directly induces the phosphorylation of
FoxO family of transcription factors, including FoxO1 (Bru-
Figure 5. Involvement of FoxO1 in mediating the effect
of PKR on IRS2. Reverse transfection of suspended
HepG2 cells was performed with scrambled siRNA
(control) or siRNA of PKR (A and B) or siRNA of FoxO1
(D) for 24 h, and the transfected cells were cultured in
regular media for another 24 h. The forward transfec-
tion of empty vector pCMV6-XL5 (pCMV6) or plasmid
containing PKR cDNA sequence (pCMV6-hPKR) was
performed, and the cells were then treated with OA (2
nM) or its vehicle, ethanol, as a control, for 1 h (C).
Reverse transfection of scramble siRNA (negative con-
trol, lanes 1 and 2) or siRNA of FoxO1 (siPKR, lanes 3
and 4) was performed, followed by the forward trans-
fection of empty vector pCMV6-XL5 (pCMV, lanes 1
and 3) or the plasmid containing PKR cDNA sequence
(hPKR, lanes 2 and 4; E). After treatment, the cells were
harvested, and Western blot analysis was performed to
detect the total and phosphorylated levels of FoxO1 (A
and C), the total levels of IRS1, IRS2, FoxO1 and -actin
(D and E), and the total and phosphorylated levels of
PKR (E). PP2A activity assay was performed to detect
the phosphatase activity of PP2A (B). The phosphoryla-
tions of FoxO1 at Ser256 normalized to the total FoxO1
protein levels (C) and the protein levels of IRS1 and
IRS2 normalized to -actins (E) are expressed as the
average of three samples  SD from three independent
experiments. Student’s t test was performed, and p val-
ues were calculated for analyzing the differences be-
tween the indicated samples.
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2005). As shown in Figure 6, the effect of PKR on FoxO1
phosphorylation stimulated by insulin is a complementary
pathway to the direct phosphorylation of FoxO1 by Akt.
Indeed we found that insulin is also able to stimulate the
phosphorylation of FoxO1, even in PKR-overexpressing
cells (data not shown). Therefore, the PKR pathway identi-
ﬁed in this study does not preclude the strong direct phos-
phorylation of FoxO1 by Akt induced by insulin.
In the present study, we identiﬁed that PKR regulates
IRS1 and IRS2 through different mechanisms. Although the
protein structures of the IRS proteins are highly conserved,
both animal and cell studies indicate that IRS1 and IRS2
serve complementary, rather than redundant, roles in insu-
lin signaling (Araki et al., 1994; Tamemoto et al., 1994; With-
ers et al., 1998; Kido et al., 2000). It has been suggested that
hepatic IRS1 and IRS2 control different aspects of hepatic
metabolism, with IRS1 more closely related to glucose ho-
meostasis and IRS2 more closely related to lipid metabolism
(Taniguchi et al., 2005). However more recently, using spe-
ciﬁc knockouts of liver IRS1 or IRS2, researchers demon-
strated that the two proteins may overlap in their insulin
action (Dong et al., 2008). Nevertheless, the different func-
tions of IRS1 and IRS2 on hepatic insulin signaling have not
been completely elucidated. Investigators have claimed that
IRS1 and IRS2 are expressed differently and exert distinct
functions under fasting and refeeding conditions (Kubota et
al., 2008). IRS1 is stably expressed in the postprandial state,
while IRS2 is highly expressed in the fasted state and down-
regulated in the fed state (Dong et al., 2008; Kubota et al.,
2008). This has been proposed to be mainly due to the
different circulating insulin levels during fasted and fed
states (Dong et al., 2008; Kubota et al., 2008). High levels of
insulin, in the fed state, suppress the IRS2 mRNA and pro-
tein expressions at the transcriptional level, through the
PI3K-Akt pathway (Hirashima et al., 2003). Because Akt
serves as a kinase that directly induces the phosphorylation
of FoxO1 (Guo et al., 1999; Barthel et al., 2005), the down-
regulation of Akt due to the low insulin levels, during
fasting, results in dephosphorylation and therefore the
translocation and activation of FoxO1 (Rena et al., 2001; Rena
et al., 2002). This then contributes to the up-regulation of
IRS2 gene transcription during fasting.
Along with the differential expression patterns of IRS1
and IRS2, a functional relay exists between IRS1 and IRS2 in
mediating hepatic insulin signaling during fasting and after
refeeding. In the fasted state, especially the late stage of
fasting, the major downstream target of insulin signaling,
PI3K, is more associated with IRS2 than IRS1 (Kubota et al.,
2008). Therefore, the elevated expression of IRS2 in the
fasted state may serve as a complementary mechanism to
compensate for the decreased level of circulating insulin
(Dong et al., 2008; Kubota et al., 2008). On the other hand,
after refeeding, the IRS1-associated PI3K starts to rise,
whereas the IRS2-associated PI3K decreases (Kubota et al.,
2008). This suggests a switch of hepatic insulin signaling hub
protein, from IRS2 in the fasting state to IRS1 in the fed state.
Thus, insulin signaling is mediated primarily through IRS1
after refeeding, whereas IRS2 plays a more predominant role
during fasting, compensating for the loss in insulin signaling
activity due to the low insulin level (Kubota et al., 2008).
Considering the distinct expressions and functions of IRS1
and IRS2 during fasted versus fed states, we propose that
PKR may regulate insulin signaling activity differentially
during the fasted versus fed states. Taking into account the
inhibitory effect of insulin on the phosphorylation of PKR, in
the present manuscript we propose that insulin suppresses
the activity of PKR in the fed state, resulting in the suppres-
sion of the negative feedbacks that functions on IRS1 Ser
phosphorylation and thereby promoting insulin signaling
activity through IRS1. On the other hand, when the circu-
lating insulin is at a low level, PKR remains at a relatively
higher activity level during the fasting (vs. fed) state, en-
hancing IRS2 gene expression through FoxO1, and promot-
ing hepatic insulin signaling to compensate for the low
insulin levels during the fasted state. Taken together, the
disparate effects of PKR on the IRS1 and IRS2 proteins may
serve as a potential mechanism by which the two IRS pro-
teins are differentially regulated.
In summary, we identiﬁed that PKR functions as a key
regulator of the central transmitters of insulin signaling in
liver cells, IRS1 and IRS2 (Figure 6). PKR induces the inhib-
itory phosphorylation of IRS at Ser312 (Figures 1–3) and
activates the transcription factor, FoxO1, which up-regulates
the protein expression level of IRS2 (Figures 4 and 5). Taken
together, PKR appears to be an important player in the
regulation of insulin signaling through the major transmit-
ters of insulin signaling, IRS1 and IRS2.
ACKNOWLEDGMENTS
We thank Linxia Zhang and Linsey Christine Seitz for their help with the western
blotting evaluation of the effect of PKR on CREB. The work was supported in part
by the National Science Foundation (CBET 0941055), the National Institutes of
Health (R01GM079688, R21CA126136 and R21RR024439), and the MSU Founda-
tion and the Center for Systems Biology.
REFERENCES
Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White, M. F. (2000). The
c-Jun NH(2)-terminal kinase promotes insulin resistance during association
with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol.
Chem. 275, 9047–9054.
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese,
C. B., and Cohen, P. (1997). Characterization of a 3-phosphoinositide-depen-
dent protein kinase which phosphorylates and activates protein kinase Bal-
pha. Curr. Biol. 7, 261–269.
Araki, E., Lipes, M. A., Patti, M. E., Bruning, J. C., Haag, B., 3rd, Johnson, R. S.,
and Kahn, C. R. (1994). Alternative pathway of insulin signalling in mice with
targeted disruption of the IRS-1 gene. Nature 372, 186–190.
Figure 6. Proposed signaling pathways through which PKR is
involved in insulin signaling network in HepG2 cells. Insulin acti-
vates insulin signaling by IR and IRS, leading to the suppression of
PKR phosphorylation at Thr451. PKR induces the phosphorylation
of IRS1 at Ser312 through two other kinases, JNK and IKK. In
addition, by activating PP2A, PKR dephosphorylates a transcription
factor, FoxO1, which up-regulates the gene expression of IRS2.
X. Yang et al.
Molecular Biology of the Cell 3456Aytug, S., Reich, D., Sapiro, L. E., Bernstein, D., and Begum, N. (2003).
Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for
increased prevalence of type 2 diabetes. Hepatology 38, 1384–1392.
Backer, J. M., Schroeder, G. G., Kahn, C. R., Myers, M. G., Jr., Wilden, P. A.,
Cahill, D. A., and White, M. F. (1992). Insulin stimulation of phosphatidyl-
inositol 3-kinase activity maps to insulin receptor regions required for endog-
enous substrate phosphorylation. J. Biol. Chem. 267, 1367–1374.
Banerjee, S., Saito, K., Ait-Goughoulte, M., Meyer, K., Ray, R. B., and Ray, R.
(2008). Hepatitis C virus core protein upregulates serine phosphorylation of
insulin receptor substrate-1 and impairs the downstream akt/protein kinase
B signaling pathway for insulin resistance. J. Virol. 82, 2606–2612.
Barthel, A., Schmoll, D., and Unterman, T. G. (2005). FoxO proteins in insulin
action and metabolism. Trends Endocrinol. Metab. 16, 183–189.
Ben-Asouli, Y., Banai, Y., Pel-Or, Y., Shir, A., and Kaempfer, R. (2002). Human
interferon-gamma mRNA autoregulates its translation through a pseudoknot
that activates the interferon-inducible protein kinase PKR. Cell 108, 221–232.
Bennett, B. L., et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun
N-terminal kinase. Proc. Natl. Acad. Sci. USA 98, 13681–13686.
Bonnet, M. C., Daurat, C., Ottone, C., and Meurs, E. F. (2006). The N-terminus
of PKR is responsible for the activation of the NF-kappaB signaling pathway
by interacting with the IKK complex. Cell Signal. 18, 1865–1875.
Bonnet, M. C., Weil, R., Dam, E., Hovanessian, A. G., and Meurs, E. F. (2000).
PKR stimulates NF-kappaB irrespective of its kinase function by interacting
with the IkappaB kinase complex. Mol. Cell. Biol. 20, 4532–4542.
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson,
M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999). Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead transcription factor.
Cell 96, 857–868.
Cuddihy, A. R., Li, S., Tam, N. W., Wong, A. H., Taya, Y., Abraham, N., Bell,
J. C., and Koromilas, A. E. (1999). Double-stranded-RNA-activated protein
kinase PKR enhances transcriptional activation by tumor suppressor p53.
Mol. Cell. Biol. 19, 2475–2484.
Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., and
White, M. F. (2008). Inactivation of hepatic Foxo1 by insulin signaling is
required for adaptive nutrient homeostasis and endocrine growth regulation.
Cell Metab 8, 65–76.
Eley, H. L., Russell, S. T., and Tisdale, M. J. (2008). Role of the dsRNA-
dependent protein kinase (PKR) in the attenuation of protein loss from muscle
by insulin and insulin-like growth factor-I (IGF-I). Mol. Cell Biochem. 313,
63–69.
Fujishiro, M., et al. (2003). Three mitogen-activated protein kinases inhibit
insulin signaling by different mechanisms in 3T3–L1 adipocytes. Mol. Endo-
crinol. 17, 487–497.
Gao, Z., Hwang, D., Bataille, F., Lefevre, M., York, D., Quon, M. J., and Ye, J.
(2002). Serine phosphorylation of insulin receptor substrate 1 by inhibitor
kappa B kinase complex. J. Biol. Chem. 277, 48115–48121.
Gross, D. N., van den Heuvel, A. P., and Birnbaum, M. J. (2008). The role of
FoxO in the regulation of metabolism. Oncogene 27, 2320–2336.
Gual, P., Gonzalez, T., Gremeaux, T., Barres, R., Le Marchand-Brustel, Y., and
Tanti, J. F. (2003). Hyperosmotic stress inhibits insulin receptor substrate-1
function by distinct mechanisms in 3T3–L1 adipocytes. J. Biol. Chem. 278,
26550–26557.
Guo, S., Rena, G., Cichy, S., He, X., Cohen, P., and Unterman, T. (1999).
Phosphorylation of serine 256 by protein kinase B disrupts transactivation by
FKHR and mediates effects of insulin on insulin-like growth factor-binding
protein-1 promoter activity through a conserved insulin response sequence.
J. Biol. Chem. 274, 17184–17192.
Herschkovitz, A., Liu, Y. F., Ilan, E., Ronen, D., Boura-Halfon, S., and Zick, Y.
(2007). Common inhibitory serine sites phosphorylated by IRS-1 kinases,
triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 282,
18018–18027.
Hirashima, Y., Tsuruzoe, K., Kodama, S., Igata, M., Toyonaga, T., Ueki, K.,
Kahn, C. R., and Araki, E. (2003). Insulin down-regulates insulin receptor
substrate-2 expression through the phosphatidylinositol 3-kinase/Akt path-
way. J. Endocrinol. 179, 253–266.
Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K.,
Karin, M., and Hotamisligil, G. S. (2002). A central role for JNK in obesity and
insulin resistance. Nature 420, 333–336.
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., and
Spiegelman, B. M. (1996). IRS-1-mediated inhibition of insulin receptor ty-
rosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.
Science 271, 665–668.
Ide, T., et al. (2004). SREBPs suppress IRS-2-mediated insulin signalling in the
liver. Nat. Cell Biol. 6, 351–357.
Imamura, T., et al. (1994). Two naturally occurring mutations in the kinase
domain of insulin receptor accelerate degradation of the insulin receptor and
impair the kinase activity. J. Biol. Chem. 269, 31019–31027.
Jammi, N. V., Whitby, L. R., and Beal, P. A. (2003). Small molecule inhibitors
of the RNA-dependent protein kinase. Biochem. Biophys. Res. Commun. 308,
50–57.
Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed,
J., Walker, J., Lin, X., White, M., and Montminy, M. (2003). cAMP promotes
pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes
Dev. 17, 1575–1580.
Kahn, B. B. (1998). Type 2 diabetes: when insulin secretion fails to compensate
for insulin resistance. Cell 92, 593–596.
Kanety, H., Hemi, R., Papa, M. Z., and Karasik, A. (1996). Sphingomyelinase
and ceramide suppress insulin-induced tyrosine phosphorylation of the in-
sulin receptor substrate-1. J. Biol. Chem. 271, 9895–9897.
Kido, Y., Burks, D. J., Withers, D., Bruning, J. C., Kahn, C. R., White, M. F., and
Accili, D. (2000). Tissue-speciﬁc insulin resistance in mice with mutations in
the insulin receptor, IRS-1, and IRS-2. J. Clin. Invest. 105, 199–205.
Kishore, N., et al. (2003). A selective IKK-2 inhibitor blocks NF-kappa B-
dependent gene expression in interleukin-1 beta-stimulated synovial ﬁbro-
blasts. J. Biol. Chem. 278, 32861–32871.
Kubota, N., et al. (2008). Dynamic functional relay between insulin receptor
substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell
Metab 8, 49–64.
Kumar, A., Yang, Y. L., Flati, V., Der, S., Kadereit, S., Deb, A., Haque, J., Reis,
L., Weissmann, C., and Williams, B. R. (1997). Deﬁcient cytokine signaling in
mouse embryo ﬁbroblasts with a targeted deletion in the PKR gene: role of
IRF-1 and NF-kappaB. EMBO J. 16, 406–416.
Lee, Y. H., Giraud, J., Davis, R. J., and White, M. F. (2003). c-Jun N-terminal
kinase (JNK) mediates feedback inhibition of the insulin signaling cascade.
J. Biol. Chem. 278, 2896–2902.
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R.,
Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., and Schlessinger, J. (1992). The SH2
and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to
ras signaling. Cell 70, 431–442.
McElduff, A., Hedo, J. A., Taylor, S. I., Roth, J., and Gorden, P. (1984). Insulin
receptor degradation is accelerated in cultured lymphocytes from patients
with genetic syndromes of extreme insulin resistance. J. Clin. Invest. 74,
1366–1374.
Mitsuhashi, S., Shima, H., Tanuma, N., Matsuura, N., Takekawa, M., Urano,
T., Kataoka, T., Ubukata, M., and Kikuchi, K. (2003). Usage of tautomycetin,
a novel inhibitor of protein phosphatase 1 (PP1), reveals that PP1 is a positive
regulator of Raf-1 in vivo. J. Biol. Chem. 278, 82–88.
Miura, A., Kajita, K., Ishizawa, M., Kanoh, Y., Kawai, Y., Natsume, Y.,
Sakuma, H., Yamamoto, Y., Yasuda, K., and Ishizuka, T. (2003). Inhibitory
effect of ceramide on insulin-induced protein kinase Czeta translocation in rat
adipocytes. Metabolism 52, 19–24.
Morimoto, H., Okamura, H., Yoshida, K., Kitamura, S., and Haneji, T. (2004).
Okadaic acid induces apoptosis through double-stranded RNA-dependent
protein kinase/eukaryotic initiation factor-2alpha pathway in human osteo-
blastic MG63 cells. J. Biochem. 136, 433–438.
Muranyi, A., Gergely, P., Nagy, G. M., and Fekete, M. I. (1997). The possible
role of protein phosphatase 2A in the sodium sensitivity of the receptor
binding of opiate antagonists naloxone and naltrindole. Brain Res. Bull. 44,
273–279.
Ozes, O. N., Akca, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E.,
and Donner, D. B. (2001). A phosphatidylinositol 3-kinase/Akt/mTOR path-
way mediates and PTEN antagonizes tumor necrosis factor inhibition of
insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci.
USA 98, 4640–4645.
Pataer, A., et al. (2002). Adenoviral transfer of the melanoma differentiation-
associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-
regulation of the double-stranded RNA-dependent protein kinase (PKR).
Cancer Res. 62, 2239–2243.
Patti, M. E., and Kahn, C. R. (1998). The insulin receptor—a critical link in
glucose homeostasis and insulin action. J. Basic Clin. Physiol. Pharmacol. 9,
89–109.
Paz, K., Hemi, R., LeRoith, D., Karasik, A., Elhanany, E., Kanety, H., and Zick,
Y. (1997). A molecular basis for insulin resistance. Elevated serine/threonine
phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamem-
PKR Regulates IRS1and IRS2
Vol. 21, October 1, 2010 3457brane region of the insulin receptor and impairs their ability to undergo
insulin-induced tyrosine phosphorylation. J. Biol. Chem. 272, 29911–29918.
Pederson, T. M., Kramer, D. L., and Rondinone, C. M. (2001). Serine/threo-
nine phosphorylation of IRS-1 triggers its degradation: possible regulation by
tyrosine phosphorylation. Diabetes 50, 24–31.
Proud, C. G. (1995). PKR: a new name and new roles. Trends Biochem. Sci. 20,
241–246.
Puigserver, P., et al. (2003). Insulin-regulated hepatic gluconeogenesis through
FOXO1-PGC-1alpha interaction. Nature 423, 550–555.
Ravichandran, L. V., Esposito, D. L., Chen, J., and Quon, M. J. (2001). Protein
kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its
ability to activate phosphatidylinositol 3-kinase in response to insulin. J. Biol.
Chem. 276, 3543–3549.
Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes 37, 1595–1607.
Rena, G., Guo, S., Cichy, S. C., Unterman, T. G., and Cohen, P. (1999).
Phosphorylation of the transcription factor forkhead family member FKHR by
protein kinase B. J. Biol. Chem. 274, 17179–17183.
Rena, G., Prescott, A. R., Guo, S., Cohen, P., and Unterman, T. G. (2001). Roles
of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in reg-
ulating 14-3-3 binding, transactivation and nuclear targetting. Biochem. J. 354,
605–612.
Rena, G., Woods, Y. L., Prescott, A. R., Peggie, M., Unterman, T. G., Williams,
M. R., and Cohen, P. (2002). Two novel phosphorylation sites on FKHR that
are critical for its nuclear exclusion. EMBO J. 21, 2263–2271.
Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I., Lee, A., Corbould, A., Dunaif,
A., and White, M. F. (2001). Insulin/IGF-1 and TNF-alpha stimulate phos-
phorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest.
107, 181–189.
Russell, S. T., Eley, H., and Tisdale, M. J. (2007). Mechanism of attenuation of
angiotensin-II-induced protein degradation by insulin-like growth factor-I
(IGF-I). Cell Signal. 19, 1583–1595.
Ruvolo, P. P., Gao, F., Blalock, W. L., Deng, X., and May, W. S. (2001).
Ceramide regulates protein synthesis by a novel mechanism involving the
cellular PKR activator RAX. J. Biol. Chem. 276, 11754–11758.
Saltiel, A. R., and Kahn, C. R. (2001). Insulin signalling and the regulation of
glucose and lipid metabolism. Nature 414, 799–806.
Samuel, V. T., et al. (2006). Targeting foxo1 in mice using antisense oligonu-
cleotide improves hepatic and peripheral insulin action. Diabetes 55, 2042–
2050.
Shim, J. H., Lee, H. K., Chang, E. J., Chae, W. J., Han, J. H., Han, D. J., Morio,
T., Yang, J. J., Bothwell, A., and Lee, S. K. (2002). Immunosuppressive effects
of tautomycetin in vivo and in vitro via T cell-speciﬁc apoptosis induction.
Proc. Natl. Acad. Sci. USA 99, 10617–10622.
Skolnik, E. Y., et al. (1993). The SH2/SH3 domain-containing protein GRB2
interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin
control of ras signalling. EMBO J. 12, 1929–1936.
Sone, H., Suzuki, H., Takahashi, A., and Yamada, N. (2001). Disease model:
hyperinsulinemia and insulin resistance. Part A-targeted disruption of insulin
signaling or glucose transport. Trends Mol. Med. 7, 320–322.
Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J.,
and Farese, R. V. (1997). Protein kinase C-zeta as a downstream effector of
phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes.
Potential role in glucose transport. J. Biol. Chem. 272, 30075–30082.
Tamemoto, H., et al. (1994). Insulin resistance and growth retardation in mice
lacking insulin receptor substrate-1. Nature 372, 182–186.
Taniguchi, C. M., Ueki, K., and Kahn, R. (2005). Complementary roles of IRS-1
and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115, 718–
727.
Taylor, S. I., and Arioglu, E. (1998). Syndromes associated with insulin resis-
tance and acanthosis nigricans. J. Basic Clin. Physiol. Pharmacol. 9, 419–439.
Taylor, S. S., Haste, N. M., and Ghosh, G. (2005). PKR and eIF2alpha: inte-
gration of kinase dimerization, activation, and substrate docking. Cell 122,
823–825.
Thirone, A. C., Huang, C., and Klip, A. (2006). Tissue-speciﬁc roles of IRS
proteins in insulin signaling and glucose transport. Trends Endocrinol. Metab
17, 72–78.
Tremblay, F., and Marette, A. (2001). Amino acid and insulin signaling via the
mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to
insulin resistance in skeletal muscle cells. J. Biol. Chem. 276, 38052–38060.
White, M. F. (1998). The IRS-signalling system: a network of docking proteins
that mediate insulin action. Mol. Cell Biochem. 182, 3–11.
Williams, B. R. (2001). Signal integration via PKR. Sci. STKE 2001, RE2.
Withers, D. J., et al. (1998). Disruption of IRS-2 causes type 2 diabetes in mice.
Nature 391, 900–904.
Woldehawariat, G., Nekhai, S., and Petryshyn, R. (1999). Differential phos-
phorylation of PKR associates with deregulation of eIF-2alpha phosphoryla-
tion and altered growth characteristics in 3T3–F442A ﬁbroblasts. Mol. Cell
Biochem. 198, 7–17.
Wu, M., Yang, X., and Chan, C. (2009). A dynamic analysis of IRS-PKR
signaling in liver cells: a discrete modeling approach. PLoS One 4, e8040.
Xu, Z., and Williams, B. R. (2000). The B56alpha regulatory subunit of protein
phosphatase 2A is a target for regulation by double-stranded RNA-dependent
protein kinase PKR. Mol. Cell. Biol. 20, 5285–5299.
Yan, L., Lavin, V. A., Moser, L. R., Cui, Q., Kanies, C., and Yang, E. (2008).
PP2A regulates the pro-apoptotic activity of FOXO1. J. Biol. Chem. 283,
7411–7420.
Yan, X. B., Battaglia, S., Boucreux, D., Chen, Z., Brechot, C., and Pavio, N.
(2007). Mapping of the interacting domains of hepatitis C virus core protein
and the double-stranded RNA-activated protein kinase PKR. Virus Res. 125,
79–87.
Yang, X., and Chan, C. (2009). Repression of PKR mediates palmitate-induced
apoptosis in HepG2 cells through regulation of Bcl-2. Cell Res. 19, 469–486.
Zhang, J., Ou, J., Bashmakov, Y., Horton, J. D., Brown, M. S., and Goldstein,
J. L. (2001). Insulin inhibits transcription of IRS-2 gene in rat liver through an
insulin response element (IRE) that resembles IREs of other insulin-repressed
genes. Proc. Natl. Acad. Sci. USA 98, 3756–3761.
Zhang, P., Jacobs, B. L., and Samuel, C. E. (2008). Loss of protein kinase PKR
expression in human HeLa cells complements the vaccinia virus E3L deletion
mutant phenotype by restoration of viral protein synthesis. J. Virol. 82,
840–848.
Zhou, H. R., Lau, A. S., and Pestka, J. J. (2003). Role of double-stranded
RNA-activated protein kinase R (PKR) in deoxynivalenol-induced ribotoxic
stress response. Toxicol. Sci. 74, 335–344.
Zick, Y. (2005). Ser/Thr phosphorylation of IRS proteins: a molecular basis for
insulin resistance. Sci. STKE 2005, pe4.
X. Yang et al.
Molecular Biology of the Cell 3458